Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population.

Gareton A, Tauziède-Espariat A, Dangouloff-Ros V, Roux A, Saffroy R, Castel D, Kergrohen T, Fina F, Figarella-Branger D, Pagès M, Bourdeaut F, Doz F, Puget S, Dufour C, Lechapt E, Chrétien F, Grill J, Varlet P.

Acta Neuropathol. 2019 Nov 1. doi: 10.1007/s00401-019-02088-8. [Epub ahead of print]

PMID:
31677015
2.

Effects in Cancer Cells of the Recombinant l-Methionine Gamma-Lyase from Brevibacterium aurantiacum. Encapsulation in Human Erythrocytes for Sustained l-Methionine Elimination.

Machover D, Rossi L, Hamelin J, Desterke C, Goldschmidt E, Chadefaux-Vekemans B, Bonnarme P, Briozzo P, Kopečný D, Pierigè F, Magnani M, Mollicone R, Haghighi-Rad F, Gaston-Mathé Y, Dairou J, Boucheix C, Saffroy R.

J Pharmacol Exp Ther. 2019 Jun;369(3):489-502. doi: 10.1124/jpet.119.256537. Epub 2019 Apr 2.

PMID:
30940696
3.

Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection.

Ruiz A, Sebagh M, Saffroy R, Allard MA, Bosselut N, Hardoin G, Vasseur J, Hamelin J, Adam R, Morère JF, Lemoine A.

BMC Cancer. 2019 Feb 22;19(1):169. doi: 10.1186/s12885-019-5365-2.

4.

Several clock genes polymorphisms are meaningful risk factors in the development and severity of cannabis addiction.

Saffroy R, Lafaye G, Desterke C, Ortiz-Tudela E, Amirouche A, Innominato P, Pham P, Benyamina A, Lemoine A.

Chronobiol Int. 2019 Jan;36(1):122-134. doi: 10.1080/07420528.2018.1523797. Epub 2018 Dec 11.

PMID:
30526093
5.

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.

Mignard X, Ruppert AM, Antoine M, Vasseur J, Girard N, Mazières J, Moro-Sibilot D, Fallet V, Rabbe N, Thivolet-Bejui F, Rouquette I, Lantuejoul S, Cortot A, Saffroy R, Cadranel J, Lemoine A, Wislez M.

J Thorac Oncol. 2018 Dec;13(12):1962-1967. doi: 10.1016/j.jtho.2018.08.008. Epub 2018 Aug 24.

6.

Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation.

Tourne M, Tauziède-Espariat A, Dezamis E, Saffroy R, Dhermain F, Chrétien F, Varlet P.

World Neurosurg. 2018 Aug;116:316-321. doi: 10.1016/j.wneu.2018.05.156. Epub 2018 May 30.

PMID:
29859360
7.

Enhancement of 5-Fluorouracil Cytotoxicity by Pyridoxal 5'-Phosphate and Folinic Acid in Tandem.

Machover D, Goldschmidt E, Mollicone R, Haghighi-Rad F, Desterke C, Gaston-Mathé Y, Saffroy R, Boucheix C, Dairou J.

J Pharmacol Exp Ther. 2018 Aug;366(2):238-243. doi: 10.1124/jpet.118.249367. Epub 2018 Jun 1.

PMID:
29858389
8.

Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.

Tauziède-Espariat A, Saffroy R, Pagès M, Pallud J, Legrand L, Besnard A, Lacombe J, Lot G, Borha A, Tazi S, Adle-Biassette H, Polivka M, Lechapt E, Varlet P.

Clin Neuropathol. 2018 Sep/Oct;37(5):209-216. doi: 10.5414/NP301104.

PMID:
29809131
9.

Rare genetic heterogeneity within single tumor discovered for the first time in colorectal liver metastases after liver resection.

Sebagh M, Bosselut N, Santos AD, Allard MA, Ruiz A, Saffroy R, Cherqui D, Vibert E, Castaing D, Adam R, Cunha AS, Lemoine A.

Oncotarget. 2018 Apr 24;9(31):21921-21929. doi: 10.18632/oncotarget.25119. eCollection 2018 Apr 24.

10.

Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation.

Puntonet J, Dangouloff-Ros V, Saffroy R, Pagès M, Andreiuolo F, Grill J, Puget S, Boddaert N, Varlet P.

J Neuroradiol. 2018 Sep;45(5):316-322. doi: 10.1016/j.neurad.2018.02.006. Epub 2018 Mar 2.

PMID:
29505840
11.

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians.

Saffroy R, Morère JF, Bosselut N, Innominato PF, Hamelin J, Trédaniel J, Masse S, Dussaule-Duchatelle V, Balaton A, Validire P, Guettier C, Bouchahda M, Lemoine A.

Oncotarget. 2017 Feb 7;8(31):50792-50803. doi: 10.18632/oncotarget.15132. eCollection 2017 Aug 1.

12.

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).

Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A.

Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17.

13.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.

Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M.

Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.

14.

Multi-factorial modulation of colorectal carcinoma cells motility - partial coordination by the tetraspanin Co-029/tspan8.

Zhu Y, Ailane N, Sala-Valdés M, Haghighi-Rad F, Billard M, Nguyen V, Saffroy R, Lemoine A, Rubinstein E, Boucheix C, Greco C.

Oncotarget. 2017 Apr 18;8(16):27454-27470. doi: 10.18632/oncotarget.16247.

15.

Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.

Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, Noé G, Farinotti R, Bonhomme-Faivre L.

Cancer Chemother Pharmacol. 2017 Apr;79(4):759-766. doi: 10.1007/s00280-017-3268-y. Epub 2017 Mar 13.

PMID:
28289864
16.

Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.

Pagès M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, Fina F, Barets D, Barret E, Lacroix L, Bielle F, Andreiuolo F, Tauziède-Espariat A, Figarella-Branger D, Puget S, Grill J, Chrétien F, Varlet P.

Brain Pathol. 2018 Jan;28(1):103-111. doi: 10.1111/bpa.12473. Epub 2017 Feb 8.

PMID:
27984673
17.

Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma.

Zanello M, Pages M, Tauziède-Espariat A, Saffroy R, Puget S, Lacroix L, Dezamis E, Devaux B, Chrétien F, Andreiuolo F, Sainte-Rose C, Zerah M, Dhermain F, Dumont S, Louvel G, Meder JF, Grill J, Dufour C, Pallud J, Varlet P.

J Neuropathol Exp Neurol. 2016 Oct;75(10):971-980. Epub 2016 Aug 18.

PMID:
27539475
18.

[Breast metastases from lung cancers with the EGFR mutation].

Assouline P, Léger-Ravet MB, Saffroy R, Hamelin J, Bénissad A, Husleag P, Lemoine A, Oliviéro G.

Rev Mal Respir. 2017 Jan;34(1):61-65. doi: 10.1016/j.rmr.2016.04.026. Epub 2016 Jun 6. French.

PMID:
27282326
19.

Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, Baldari G, De Filippo M, Ferretti S, Moroni G, Foti R, Di Gangi M, Jeannin G, Saffroy R, Emile JF, Buzio C, Vaglio A.

Blood. 2015 Sep 3;126(10):1163-71. doi: 10.1182/blood-2015-01-620377. Epub 2015 Jun 3.

20.

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.

Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M, Poulot V, Schlick L, Moro-Sibilot D, Antoine M, Cadranel J, Lemoine A, Wislez M.

Ann Oncol. 2015 Aug;26(8):1748-53. doi: 10.1093/annonc/mdv232. Epub 2015 May 12.

PMID:
25969368
21.

Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis.

Héritier S, Saffroy R, Radosevic-Robin N, Pothin Y, Pacquement H, Peuchmaur M, Lemoine A, Haroche J, Donadieu J, Emile JF.

Blood. 2015 Apr 9;125(15):2448-9. doi: 10.1182/blood-2015-01-625491. No abstract available.

PMID:
25858893
22.

Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?

Allard MA, Saffroy R, de la Maisonneuve PB, Ricca L, Bosselut N, Hamelin J, Lecorche E, Bejarano MA, Innominato P, Sebagh M, Adam R, Morère JF, Lemoine A.

Target Oncol. 2015 Sep;10(3):415-21. doi: 10.1007/s11523-014-0346-5. Epub 2014 Nov 26.

PMID:
25420993
23.

Mitochondrial roles and cytoprotection in chronic liver injury.

Degli Esposti D, Hamelin J, Bosselut N, Saffroy R, Sebagh M, Pommier A, Martel C, Lemoine A.

Biochem Res Int. 2012;2012:387626. doi: 10.1155/2012/387626. Epub 2012 Jun 15.

24.

Association between a polymorphism in the promoter of a glutamate receptor subunit gene (GRIN2A) and alcoholism.

Domart MC, Benyamina A, Lemoine A, Bourgain C, Blecha L, Debuire B, Reynaud M, Saffroy R.

Addict Biol. 2012 Jul;17(4):783-5. doi: 10.1111/j.1369-1600.2011.00321.x. Epub 2011 Apr 20.

PMID:
21507155
25.

Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.

Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M.

Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48. doi: 10.1007/s00280-010-1327-8. Epub 2010 Apr 17.

PMID:
20401611
26.

Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.

Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gorden L, Guettier C, Adam R, Lévi F.

Cancer Chemother Pharmacol. 2010 Aug;66(3):605-9. doi: 10.1007/s00280-010-1298-9. Epub 2010 Apr 2.

PMID:
20361188
27.

Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.

Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N, Guettier C, Saffroy R, Innominato P, Almohamad W, Brahimi N, Haydar M, Goldschmidt E.

Biomed Pharmacother. 2010 Feb;64(2):83-7. doi: 10.1016/j.biopha.2009.11.001. Epub 2009 Dec 9.

PMID:
20044233
28.

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.

Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, Farinotti R, Bonhomme-Faivre L.

Med Oncol. 2010 Dec;27(4):1066-72. doi: 10.1007/s12032-009-9336-3. Epub 2009 Oct 28.

PMID:
19862647
29.

Association between MTHFR 677C-T polymorphism and alcohol dependence according to Lesch and Babor typology.

Benyamina A, Saffroy R, Blecha L, Pham P, Karila L, Debuire B, Lemoine A, Reynaud M.

Addict Biol. 2009 Sep;14(4):503-5. doi: 10.1111/j.1369-1600.2009.00169.x. Epub 2009 Jul 24.

PMID:
19650814
30.

Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study.

Chiappini F, Teicher E, Saffroy R, Debuire B, Vittecoq D, Lemoine A.

Curr HIV Res. 2009 Mar;7(2):244-53.

PMID:
19275594
31.

Protective effect against alcohol dependence of the thermolabile variant of MTHFR.

Saffroy R, Benyamina A, Pham P, Marill C, Karila L, Reffas M, Debuire B, Reynaud M, Lemoine A.

Drug Alcohol Depend. 2008 Jul 1;96(1-2):30-6. doi: 10.1016/j.drugalcdep.2008.01.016. Epub 2008 Mar 7.

PMID:
18328637
32.

New perspectives and strategy research biomarkers for hepatocellular carcinoma.

Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B.

Clin Chem Lab Med. 2007;45(9):1169-79. Review.

PMID:
17635075
33.

Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma.

Riou P, Saffroy R, Chenailler C, Franc B, Gentile C, Rubinstein E, Resink T, Debuire B, Piatier-Tonneau D, Lemoine A.

FASEB J. 2006 Nov;20(13):2291-301.

PMID:
17077306
34.

Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism.

Théou-Anton N, Tabone S, Brouty-Boyé D, Saffroy R, Ronnstrand L, Lemoine A, Emile JF.

Br J Cancer. 2006 Apr 24;94(8):1180-5.

35.

Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma.

Scatton O, Chiappini F, Riou P, Marconi A, Saffroy R, Bralet MP, Azoulay D, Boucheix C, Debuire B, Uzan G, Lemoine A.

Oncogene. 2006 Jul 6;25(29):4067-75. Epub 2006 Feb 20.

PMID:
16491122
36.

Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray.

Chiappini F, Barrier A, Saffroy R, Domart MC, Dagues N, Azoulay D, Sebagh M, Franc B, Chevalier S, Debuire B, Dudoit S, Lemoine A.

Lab Invest. 2006 Feb;86(2):154-65.

37.

KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs).

Tabone S, Théou N, Wozniak A, Saffroy R, Deville L, Julié C, Callard P, Lavergne-Slove A, Debiec-Rychter M, Lemoine A, Emile JF.

Biochim Biophys Acta. 2005 Jun 30;1741(1-2):165-72. Epub 2005 Apr 13.

38.

[Molecular biology and hepatocellular carcinoma: current status and future prospects].

Saffroy R, Pham P, Lemoine A, Debuire B.

Ann Biol Clin (Paris). 2004 Nov-Dec;62(6):649-56. Review. French.

39.

Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients.

Chiappini F, Teicher E, Saffroy R, Pham P, Falissard B, Barrier A, Chevalier S, Debuire B, Vittecoq D, Lemoine A.

Lab Invest. 2004 Jul;84(7):908-14.

40.

High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors.

Théou N, Tabone S, Saffroy R, Le Cesne A, Julié C, Cortez A, Lavergne-Slove A, Debuire B, Lemoine A, Emile JF.

Biochim Biophys Acta. 2004 Apr 5;1688(3):250-6.

41.

The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis.

Saffroy R, Pham P, Chiappini F, Gross-Goupil M, Castera L, Azoulay D, Barrier A, Samuel D, Debuire B, Lemoine A.

Carcinogenesis. 2004 Aug;25(8):1443-8. Epub 2004 Mar 19.

PMID:
15033905
42.

Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers.

Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, Veillhan LA, Delvart V, Chevalier S, Bismuth H, Debuire B, Lemoine A.

Carcinogenesis. 2004 Apr;25(4):541-7. Epub 2003 Dec 4.

PMID:
14656944
43.

Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma.

Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V, Tindilière F, Laurent A, Bellin MF, Bismuth H, Debuire B, Lemoine A.

Ann Surg. 2003 Aug;238(2):241-8.

44.

Analysis of chromosomal instability in pulmonary or liver metastases and matched primary hepatocellular carcinoma after orthotopic liver transplantation.

Gross-Goupil M, Riou P, Emile JF, Saffroy R, Azoulay D, Lacherade I, Receveur A, Piatier-Tonneau D, Castaing D, Debuire B, Lemoine A.

Int J Cancer. 2003 May 10;104(6):745-51.

46.

Investigation in liver tissues and cell lines of the transcription of 13 genes mapping to the 16q24 region that are frequently deleted in hepatocellular carcinoma.

Riou P, Saffroy R, Comoy J, Gross-Goupil M, Thiéry JP, Emile JF, Azoulay D, Piatier-Tonneau D, Lemoine A, Debuire B.

Clin Cancer Res. 2002 Oct;8(10):3178-86.

47.

Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis.

Machover D, Zittoun J, Saffroy R, Broët P, Giraudier S, Magnaldo T, Goldschmidt E, Debuire B, Orrico M, Tan Y, Mishal Z, Chevallier O, Tonetti C, Jouault H, Ulusakarya A, Tanguy ML, Metzger G, Hoffman RM.

Cancer Res. 2002 Aug 15;62(16):4685-9.

48.

Analysis of alterations of WFDC1, a new putative tumour suppressor gene, in hepatocellular carcinoma.

Saffroy R, Riou P, Soler G, Azoulay D, Emile JF, Debuire B, Lemoine A.

Eur J Hum Genet. 2002 Apr;10(4):239-44.

49.

Accumulation of an inactive form of p53 protein in cells treated with TNF alpha.

Drané P, Leblanc V, Miro-Mur F, Saffroy R, Debuire B, May E.

Cell Death Differ. 2002 May;9(5):527-37.

50.

Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants.

Lemoine A, Pham P, Azoulay D, Saliba F, Emile JF, Saffroy R, Broet P, Bismuth H, Samuel D, Debuire B.

Blood. 2001 Sep 1;98(5):1332-8.

PMID:
11520779

Supplemental Content

Loading ...
Support Center